

### **Amendment to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

### **Listing of Claims**

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (currently amended) A method for screening a test substance for COX-2 inhibitory activity comprising:
  - (a) contacting the test substance with indicator cells which express a GTPase-deficient mutant form of the  $\alpha$ -subunit of protein G12, wherein the G12 protein  $\alpha$ -subunit mutant comprises the Q229L mutation, which mutant  $\alpha$ -subunit has the capacity to induce the production of arachidonic acid in the indicator cells, and induces production of COX-2 in the indicator cells; and
  - (b) determining the level of one or more prostaglandins produced by the indicator cells in the presence and absence of the test substance, a decrease in production of said prostaglandin by the indicator cells in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
7. (canceled)
8. (currently amended) A method according to claim ~~76~~ wherein the prostaglandin level is assayed in the media surrounding the indicator cells, in the indicator cells or in a component of the indicator cells.

9. (currently amended) A method according to claim 86 wherein the prostaglandin level is assayed by a prostaglandin immunoassay.

10. (currently amended) A method according to claim 96 wherein the prostaglandin immunoassay comprises a competitive immunoassay.

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)